about
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study.Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyTransfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trialAbacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan AfricaStrategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism.Newborn screening for inborn errors of metabolism: a systematic review.Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.Once vs twice-daily abacavir and lamivudine in African children.Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY TrialA comparison of the effects of insulin-like growth factor-I, insulin and combined infusions of insulin and insulin-like growth factor-I on glucose metabolism in dogsThe effects of growth hormone on protein metabolism in adult growth hormone deficient patientsProtein metabolism in growth hormone deficiency, and effects of growth hormone replacement therapyPharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets
P50
Q30994943-B8330CEA-5110-4AF3-B1DC-FCA650C9BEB3Q33885987-E869A19B-5A78-4644-8D31-795DDA857F9DQ35205900-5307532D-F0DB-4A08-B5B5-C4DA42E14742Q36416849-51AE8AAD-62A3-474C-BC61-3F8A07D85941Q36501872-B930A35A-A576-47E6-9147-9DCA0612515AQ37620109-8B404F9D-E877-4948-B90A-85A21DB0D1BDQ37792092-A7BEF58A-663A-46F4-93AF-3804A44EC0B9Q38476692-C4B02DA5-70CA-4188-AC31-3C42D113339DQ38479235-38A4C1F1-2339-464F-86B6-95EE4C37849EQ38849598-E3B7F46F-4746-4D59-A7CF-7416D2C4BEBBQ38852917-34DBBB92-D1E8-40D3-9ED7-E32240EE0078Q38855053-DAC73093-5C7E-467B-8731-843732CD199AQ38857895-75CD6D20-1D0F-4ADC-8978-6E3F99A53D3CQ38871183-7EB223D9-0FF7-4DCC-A557-9C6ED887FACBQ42254681-13713E6B-A8FE-49D3-AAA1-A31FEB857B05Q43454587-2D51CAC6-188E-4B6B-A44D-3D2FAC9CFDAFQ44990846-15018915-BA48-4E8C-B75E-771B8246BF72Q46801510-D08ABC28-F73C-4D3F-88A3-1A236D133D06Q47130269-986BB6BA-3ABD-4073-9458-A2113452C83BQ47133943-7449AA07-592A-4B19-9E2C-2A9F17052304Q52589311-7BD6CECC-2523-4BA1-86DC-D2D3EBE17F09Q53691502-5AC16375-A122-4E5A-8154-F1DBA6755F1EQ56912547-F800AE7F-FDF2-4EDB-A6DC-466C87690391Q71290819-98F0F67F-CD94-44EB-BA0B-9B887B5A8AE8Q72800968-237E803D-4D1D-4CBF-9931-9371973C61EDQ72859440-7FFF82AC-ABD9-420B-9E93-7229676F43E6Q84473631-DE076816-B048-4541-AEA6-1E2BEFF6771C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Margaret Thomason
@ast
Margaret Thomason
@en
Margaret Thomason
@es
Margaret Thomason
@nl
type
label
Margaret Thomason
@ast
Margaret Thomason
@en
Margaret Thomason
@es
Margaret Thomason
@nl
altLabel
M Thomason
@en
M. Thomason
@en
prefLabel
Margaret Thomason
@ast
Margaret Thomason
@en
Margaret Thomason
@es
Margaret Thomason
@nl
P106
P21
P31
P496
0000-0003-3590-0140